Literature DB >> 12413806

Models and methods for studying insurmountable antagonism.

Georges Vauquelin1, Isabelle Van Liefde, Patrick Vanderheyden.   

Abstract

Insurmountable antagonists depress the concentration-response curves of subsequently added agonists. The longevity of the antagonist-receptor complex and the existence of allosteric binding sites are the most frequent explanations for this phenomenon. Yet, observed antagonist behaviour often depends on the tissue, the animal species, the duration of the measured response and the study design. Intact cell studies allow greater flexibility and tighter control of the experimental conditions and therefore have the potential to offer a better insight into the molecular basis of insurmountable antagonism.

Mesh:

Year:  2002        PMID: 12413806     DOI: 10.1016/s0165-6147(02)02081-3

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  16 in total

Review 1.  Elusive equilibrium: the challenge of interpreting receptor pharmacology using calcium assays.

Authors:  Steven J Charlton; Georges Vauquelin
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

Review 2.  Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action.

Authors:  Georges Vauquelin; Steven J Charlton
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

3.  Estimation of the dissociation rate of unlabelled ligand-receptor complexes by a 'two-step' competition binding approach.

Authors:  A Packeu; M Wennerberg; A Balendran; G Vauquelin
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

Review 4.  On the different experimental manifestations of two-state 'induced-fit' binding of drugs to their cellular targets.

Authors:  Georges Vauquelin; Isabelle Van Liefde; David C Swinney
Journal:  Br J Pharmacol       Date:  2016-03-15       Impact factor: 8.739

5.  Modelling of alpha1-adrenoceptor-mediated temporal dynamics of inotropic response in rat heart to assess ligand binding and signal transduction parameters.

Authors:  P Sermsappasuk; M Weiss
Journal:  Br J Pharmacol       Date:  2009-02-13       Impact factor: 8.739

6.  A study of the molecular mechanism of binding kinetics and long residence times of human CCR5 receptor small molecule allosteric ligands.

Authors:  David C Swinney; Paul Beavis; Kai-Ting Chuang; Yue Zheng; Ina Lee; Peter Gee; Jerome Deval; David M Rotstein; Marianna Dioszegi; Palani Ravendran; Jun Zhang; Surya Sankuratri; Rama Kondru; Georges Vauquelin
Journal:  Br J Pharmacol       Date:  2014-07       Impact factor: 8.739

7.  Inhibition of human prostate smooth muscle contraction by the LIM kinase inhibitors, SR7826 and LIMKi3.

Authors:  Qingfeng Yu; Christian Gratzke; Yiming Wang; Annika Herlemann; Christian Maximilian Sterr; Beata Rutz; Anna Ciotkowska; Xiaolong Wang; Frank Strittmatter; Christian G Stief; Martin Hennenberg
Journal:  Br J Pharmacol       Date:  2018-04-29       Impact factor: 8.739

8.  Molecular characterisation of the interactions between olmesartan and telmisartan and the human angiotensin II AT1 receptor.

Authors:  M T Le; M K Pugsley; G Vauquelin; I Van Liefde
Journal:  Br J Pharmacol       Date:  2007-06-18       Impact factor: 8.739

9.  Diisothiocyanate derivatives as potent, insurmountable antagonists of P2Y6 nucleotide receptors.

Authors:  Liaman K Mamedova; Bhalchandra V Joshi; Zhan-Guo Gao; Ivar von Kügelgen; Kenneth A Jacobson
Journal:  Biochem Pharmacol       Date:  2004-05-01       Impact factor: 5.858

10.  Isolation and pharmacological characterization of AdTx1, a natural peptide displaying specific insurmountable antagonism of the alpha1A-adrenoceptor.

Authors:  L Quinton; E Girard; A Maiga; M Rekik; P Lluel; G Masuyer; M Larregola; C Marquer; J Ciolek; T Magnin; R Wagner; J Molgó; R Thai; C Fruchart-Gaillard; G Mourier; J Chamot-Rooke; A Ménez; S Palea; D Servent; N Gilles
Journal:  Br J Pharmacol       Date:  2009-12-15       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.